Summary
The prospective prognostic significance of flow cytometry derived DNA-ploidy status, the level of the S-phase fraction (SPF), estrogen receptor (ER) content, and combinations of these factors, was evaluated with respect to overall survival (OS) in a series of 516 breast cancer patients who were without signs of residual or distant disease after primary completed treatment. The median duration of survival follow-up time was ten years (range, 95–148 months) for surviving patients.
Of the single factors, ER was the only significant predictor among node-negative patients; the ten-year OS rate was 71% in cases with ER-rich tumors vs. 62% for ER-poor tumors (p=0.03). Where tumors were both non-diploid and ER-poor, the ten-year OS rate was 58%, as compared to 75% for the remaining node-negative patients (p=0.003), who constituted a low-risk group whose survival was comparable with that in the age-matched normal population.
Among patients with 1–3 positive nodes, the ten-year OS rate was 65% in patients whose tumors had an SPF <7.3% vs. 50% if the SPF was ≥7.3% (p=0.01), and 58% in cases with ER-rich tumors vs. 45% where the tumors were ER-poor (p=0.02).
In a multivariate analysis, apart from age and menopausal status the combination of ploidy status and ER content was the significant (p=0.002) predictor of OS in node-negative patients. Thus, combining ploidy and ER status, both of which are variables easily determined, enabled the selection of a subgroup of patients at high risk of relapse and reduced survival whose prognosis should be improved by effective adjuvant systemic treatment, whereas the remaining low risk N0 patients can not be expected to derive any survival benefit from adjuvant therapy since their predicted survival is already on a par with that of the general population.
Similar content being viewed by others
References
Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187, 1989
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71–85, 1992
Kaufmann M: Adjuvant systemic therapy in node-negative breast cancer.In Goldhirsch A (ed) Endocrine Therapy of Breast Cancer IV. Springer-Verlag, 1990, pp 67–76
Henderson IC, Hayes DF, Parker LM, Love S, Garber JE, Recht A, Breitmeyer JB, Harris JR, Canellos GP: Adjuvant systemic therapy for patients with node-negative tumors. Cancer 65:2132–2147, 1990
Ewers S-B, Attewell R, Baldetorp B, Borg Å, Långström E, Killander D: Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Can Res Treat 20:93–108, 1992
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627–633, 1989
Sigurdsson H, Baldetorp B, Borg Å, Dalberg M, Fernö M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322:1045–1053, 1990
Ewers S-B, Långström E, Baldetorp B, Killander D: Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 5:408–419, 1984
Hiddeman W, Schumann J, Andreeff M, et al: Convention of nomenclature for DNA cytometry. Cytometry 5:445–446, 1984
Baisch H, Gohde W, Linden WA: Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 12:31–39, 1975
Norgren A, Borg Å, Fernö M, Johansson U, Lindahl B, Tsiobanelis K: Improved method of assay of estradiol and progesterone receptors with special reference to breast cancer. Anticancer Res 2:315–320, 1982
Fernö M, Borg Å, Johansson U, et al: Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples: a study with special reference to age at diagnosis and stability of analysis. Acta Oncol 29:129–135, 1990
Lee E, Desu M: A computer program for comparing k samples with right censored data. Comput Programs Biomed 2:315–321, 1972
Hakulinen T, Abeywickrama KH: A computer program package for relative survival analysis. Comput Programs Biomed 19:197–207, 1985
Frierson HF: Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. Am J Surg Pathol 15:358–367, 1991
Kallioniemi O-P, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Koivula T: Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 56:637–642, 1987
Toikkanen S, Joensuu H, Klemi P: The prognostic significance of nuclear DNA content in invasive breast cancer — a study with long term follow-up. Br J Cancer 60:693–700, 1989
Lewis WE: Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients. Cancer 65:2315–2320, 1990
Beerman H, Kluin M, van de Velde CJH, Hermans J, Cornelisse CJ: Letter to the Editor. N Engl J Med 321:473–474, 1989
Muss HB, Kute TE, Case LD, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64:1894–1900, 1989
Keyhani-Rofagha S, O'Toole RV, Farrar WB, Sickle-Santanello B, DeCenzo J, Young D: Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 65:1577–1582, 1990
Fisher B, Redmond C, Fisher E, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project protocol B-06. J Clin Oncol 6:1076–1087, 1988
Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15(Suppl 1):20–25, 1988
Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53:2525–2529, 1984
O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA: Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 26:1035–1038, 1990
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: A long-term follow-up study of survival in Stage I (T1N0M0) and Stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355–366, 1989
O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA: Node-negative breast cancer: Prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8:2040–2046, 1990
Baldetorp B, Dalberg M, Holst U, Lindgren G: Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. Cytometry 10:695–705, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ewers, SB., Attewell, R., Baldetorp, B. et al. Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas — a 10 year survival study. Breast Cancer Res Tr 24, 115–126 (1992). https://doi.org/10.1007/BF01961244
Issue Date:
DOI: https://doi.org/10.1007/BF01961244